Axsome Therapeutics (AXSM) Upgraded to “Buy” at ValuEngine

ValuEngine upgraded shares of Axsome Therapeutics (NASDAQ:AXSM) from a hold rating to a buy rating in a research note released on Thursday morning.

AXSM has been the subject of several other research reports. HC Wainwright reissued a buy rating and set a $10.00 price target on shares of Axsome Therapeutics in a research report on Wednesday, December 5th. LADENBURG THALM/SH SH reiterated a positive rating and set a $45.00 target price (up from $34.00) on shares of Axsome Therapeutics in a report on Monday. Zacks Investment Research lowered shares of Axsome Therapeutics from a hold rating to a sell rating in a report on Wednesday, September 12th. Cantor Fitzgerald initiated coverage on shares of Axsome Therapeutics in a report on Thursday, November 15th. They set an overweight rating and a $16.00 target price for the company. Finally, BTIG Research increased their target price on shares of Axsome Therapeutics to $20.00 and gave the stock a buy rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. Axsome Therapeutics currently has a consensus rating of Buy and a consensus target price of $24.00.

AXSM stock traded down $0.05 during trading on Thursday, hitting $7.36. 2,464,900 shares of the company traded hands, compared to its average volume of 11,490,425. The stock has a market capitalization of $225.09 million, a PE ratio of -5.94 and a beta of -0.07. Axsome Therapeutics has a 1 year low of $1.94 and a 1 year high of $9.16. The company has a debt-to-equity ratio of 6.00, a current ratio of 1.46 and a quick ratio of 1.46.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Friday, November 9th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.02. Analysts anticipate that Axsome Therapeutics will post -1.13 EPS for the current year.

Hedge funds have recently made changes to their positions in the stock. Worth Venture Partners LLC purchased a new stake in Axsome Therapeutics in the third quarter worth $138,000. Sio Capital Management LLC lifted its position in shares of Axsome Therapeutics by 115.5% in the 3rd quarter. Sio Capital Management LLC now owns 416,458 shares of the company’s stock worth $1,437,000 after purchasing an additional 223,168 shares during the period. Finally, Alethea Capital Management LLC lifted its position in shares of Axsome Therapeutics by 102.1% in the 3rd quarter. Alethea Capital Management LLC now owns 547,443 shares of the company’s stock worth $1,889,000 after purchasing an additional 276,620 shares during the period. 11.85% of the stock is owned by institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.

See Also: How is net asset value different from market price?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply